Fore Pharma’s latest report ‘Global Lysosomal Storage Diseases Drug Pipeline Capsule – 2011’ is an outline of all the key research and development (R&D) activities of the global lysosomal storage diseases drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the lysosomal storage diseases drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Lysosomal Storage Diseases: Overview
- Lysosomal Storage Diseases Drug Pipeline Overview
- Lysosomal Storage Diseases Phase 3 Clinical Trial Drug Pipeline Insights
- Lysosomal Storage Diseases Phase 2 Clinical Trial Drug Pipeline Insights
- Lysosomal Storage Diseases Phase 1 Clinical Trial Drug Pipeline Insights
- Lysosomal Storage Diseases Preclinical Research Drug Pipeline Insights
- Lysosomal Storage Diseases Drug Discovery Pipeline Insights
- Geographic Landscape of Lysosomal Storage Diseases R&D Activities
- Lysosomal Storage Diseases R&D Activities in North America
- Lysosomal Storage Diseases R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Lysosomal Storage Diseases Drug Market

1. Lysosomal Storage Diseases: Disease Definition
2. Lysosomal Storage Diseases Drug Pipeline Overview
3. Lysosomal Storage Diseases Phase 3 Clinical Trial Drug Pipeline Insights
4. Lysosomal Storage Diseases Phase 2 Clinical Trial Drug Pipeline Insights
5. Lysosomal Storage Diseases Phase 1 Clinical Trial Drug Pipeline Insights
6. Lysosomal Storage Diseases Preclinical Research Drug Pipeline Insights
7. Lysosomal Storage Diseases Drug Discovery Pipeline Insights
8. Geographic Landscape of Lysosomal Storage Diseases R&D Activities
8.1 Lysosomal Storage Diseases R&D Activities in North America
8.2 Lysosomal Storage Diseases R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Lysosomal Storage Diseases Drug Market
10 Research Methodology Table 1: Lysosomal Storage Diseases Drug Pipeline: Phase 3 Clinical Trial

Table 2: Lysosomal Storage Diseases Drug Pipeline: Phase 2 Clinical Trial
Table 3: Lysosomal Storage Diseases Drug Pipeline: Phase 1 Molecules
Table 4: Lysosomal Storage Diseases Drug Pipeline: Preclinical Research
Table 5: Lysosomal Storage Diseases R&D Activities by Geography
Table 6: Lysosomal Storage Diseases Drug Pipeline: North America
Table 7: Lysosomal Storage Diseases Drug Pipeline: Europe
Table 8: Lysosomal Storage Diseases Drug Pipeline: Licensing Activities

Figure 1 : Lysosomal Storage Diseases Drug Pipeline Molecules by Stages
Figure 2 : Lysosomal Storage Diseases R&D Activities by Geography